Results 11 to 20 of about 136,022 (256)

Anti-VEGFR2 F(ab′)2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy

Nature Communications, 2023
Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab′)2 fragmented vascular endothelial growth factor receptor 2 antibody (anti-VEGFR2 (F(ab′)
Di Liu, Yanling Song, Hui Chen, Yuchan You, Luwen Zhu, Jucong Zhang, Xinyi Xu, Jiahao Hu, Xiajie Huang, Xiaochuan Wu, Xiaoling Xu, Saiping Jiang, Yongzhong Du   +12 more
doaj   +1 more source

A Vaccine Against Group B Streptococcus: Recent Advances [PDF]

, 2020
Group B streptococcus (GBS) causes a high burden of neonatal and infant disease globally. Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and infant GBS disease and has been identified as a priority by the World ...
Carreras-Abad, C, Heath, PT, Le Doare, K, Ramkhelawon, L   +3 more
core   +2 more sources

Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. [PDF]

, 2016
First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.
Barile, Elisa, Das, Swadesh K, De, Surya K, Emdad, Luni, Fisher, Paul B, Morvaridi, Susan Kharagh, Pandol, Stephen J, Pellecchia, Maurizio, Quinn, Bridget A, Sarkar, Devanand, Stebbins, John L, Wang, Si   +11 more
core   +5 more sources

Exploration of the antibody–drug conjugate clinical landscape

mAbs, 2023
The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial recent developmental investment and subsequent drug approvals over the past 6 years. In November 2022, ElahereTM became the latest ADC to be approved by the US Food and
Heather Maecker, Vidya Jonnalagadda, Sunil Bhakta, Vasu Jammalamadaka, Jagath R. Junutula   +4 more
doaj   +1 more source

Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. [PDF]

, 2019
Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides (ASOs), have great potential to drug the undruggable genome. Targeting siRNAs and ASOs to specific cell types of interest has driven dramatic improvement in efficacy and ...
Cui, Xianshu, Dowdy, Steven F, Huggins, Ian J, Jadhav, Satish, Medina, Carlos A, Springer, Aaron D, van den Berg, Arjen   +6 more
core   +1 more source

A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development

Antibodies, 2019
Antibodies, antibody-like molecules, and therapeutics incorporating antibodies as a targeting moiety, such as antibody-drug conjugates, offer significant potential for the development of highly efficacious drugs against a wide range of disorders. Despite
Gareth D. Healey, Asa Frostell, Tim Fagge, Deyarina Gonzalez, R. Steven Conlan   +4 more
doaj   +1 more source

Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment [PDF]

, 2014
The rapidly increasing interest in the synthesis of antibody–drug conjugates as powerful targeted anticancer agents demonstrates the growing appreciation of the power of antibodies and antibody fragments as highly selective targeting moieties.
Boyle, Ross W., Bryden, Francesca, Caddick, Stephen, Chudasama, Vijay, Maruani, Antoine, Savoie, Huguette, Smith, Mark E. B.   +6 more
core   +1 more source

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. [PDF]

, 2015
Although recent methods for the engineering of antibody-drug conjugates (ADCs) have gone some way to addressing the challenging issues of ADC construction, significant hurdles still remain.
Caddick, S, Chester, KA, Chudasama, V, Maruani, A, Miranda, E, Smith, ME   +5 more
core   +1 more source

Antibody drug conjugates

Indian Journal of Medical and Paediatric Oncology, 2020
Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj   +1 more source

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Haematologica, 2020
Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematological cancers. Here, we report preclinical data on the anti-tumor activity of the first-in-class antibody drug conjugate MEN1309/OBT076 targeting
Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, Francesca Guidetti, Giulio Sartori, Roberta Bordone, Alberto J. Arribas, Luciano Cascione, Mario Bigioni, Giuseppe Merlino, Alessio Fiascarelli, Alessandro Bressan, Afua Adjeiwaa Mensah, Gaetanina Golino, Renzo Lucchini, Elena Bernasconi, Davide Rossi, Emanuele Zucca, Georg Stussi, Anastasios Stathis, Robert S. Boyd, Rachel L. Dusek, Arnima Bisht, Nickolas Attanasio, Christian Rohlff, Andrea Pellacani, Monica Binaschi, Francesco Bertoni   +27 more
doaj   +1 more source